Tango Therapeutics, Inc. · NASDAQ:TNGX
Tango Therapeutics — Investor Presentation (August 2026)
36 slides from Tango Therapeutics's investor presentation, August 2026
Slide 1: Investor presentation
Investor presentation August 2026
Slide 2: Disclaimer and safe harbor statement
Disclaimer and safe harbor statement Certain statements in this presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or
Slide 3: Leaders in PRMT5 science, advancing to late-stage development
Leaders in PRMT5 science, advancing to late-stage development based on compelling clinical data Strong balance sheet + well Compelling data funded to execute clinical for vopimetostat + RAS(ON) development plan with $1B+ inhibitors supports in cash on hand development in 1L PDAC Vopimetostat PRMT5 f
Slide 4: Wholly-owned pipeline targeting MTAP deleted cancers
Wholly-owned pipeline targeting MTAP deleted cancers STATUS & ANTICIPATED MOLECULE INDICATION COMBINATION CLINICAL PHASE MILESTONES PRE-CLINICAL PHASE 1/2 PHASE 3 Study design to be finalized 1L PDAC* + daraxonrasib 2H 2026 Expansion of ongoing Phase 2L PDAC + daraxonrasib 1/2 study Vopimetostat + d
Slide 5: MTAP-del cancers are uniquely sensitive to PRMT5 inhibition
MTAP-del cancers are uniquely sensitive to PRMT5 inhibition X deletion causes MTA accumulation only in cancer cells X MTAP MTA MTA activates PRMT5 partially inhibits PRMT5 SAM MTA MTA by replacing SAM in normal cells Vopimetostat + TNG456 PRMT5 inhibits PRMT5 only in MTAP-del cancer cells when MTA i
Slide 6: Vopimetostat and TNG456 selectively inhibit PRMT5 in MTAP-del cancers
Vopimetostat and TNG456 selectively inhibit PRMT5 in MTAP-del cancers Normal cells MTAP-del cancer cells Key points • Vopimetostat and TNG456 selectively kill MTAP-del cancer cells while largely sparing normal cells SAM • Vopimetostat and TNG456 lock PRMT5-MTA into the inactive state (MTA cooperativ
Slide 7: ~60,000 patients with MTAP del metastatic cancers annually in the US
~60,000 patients with MTAP del metastatic cancers annually in the US MTAP del % Number of cases NSCLC 15% Plan to initially prioritize PDAC Pancreatic 40% GBM/glioma 45% • Potential blockbuster opportunity for Head and Neck 16% vopimetostat in PDAC alone Bladder 25% − Nearly all patients with an MTA
Slide 8: Vopimetostat: Potential best-in-class PRMT5 Inhibitor
Vopimetostat: Potential best-in-class PRMT5 Inhibitor Advancing Toward Pivotal Trials with Chemotherapy- Free Combination Approaches in Pancreatic Cancer Differentiated Clinically Combination Expansion profile validated strategy potential Highly selective and potent Robust monotherapy Targeted combi
Slide 9: Vopimetostat + RAS(ON) inhibitors
Vopimetostat + RAS(ON) inhibitors 9
Slide 10: Evolution of standard of care for pancreatic cancer
Evolution of standard of care for pancreatic cancer CHEMOTHERAPY RAS INHIBITORS1 RAS INHIBITORS + PRMT5 INHIBITORS Current standard; Improved response Increased response rate and Limited efficacy and durability prolonged durability Today Emerging Potential Next Generation 1. Wolpin et al. ASCO, 2026
Slide 11: PRMT5 + RAS inhibition demonstrated preclinical synergy
PRMT5 + RAS inhibition demonstrated preclinical synergy In vivo model demonstrated striking combination efficacy Key points MTAP-null, KRASG12D PDAC CDX (KP4) • KRAS inhibition + PRMT5 inhibition is synergistic in multiple preclinical models1 • Clinical data to date support synergy of combination in
Slide 12: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase 1 dose escalation trial Vopimetostat + daraxonrasib: • Dose escalation range: Any RAS mut vopimetostat + 200 mg – 250 mg vopimetostat QD 2L+ MTAP-del/ daraxonrasib + 100 mg daraxonrasib QD RAS mut pancreatic and lung cancer vopim
Slide 13: Vopimetostat + daraxonrasib in MTAPdel 2/3L PDAC: ORR 92%
Vopimetostat + daraxonrasib in MTAPdel 2/3L PDAC: ORR 92% - 11 PRs in 12 patients 20 Line of therapy: N=12 2 2 2 3 3 2 3 3 3 3 1 2 0 ORR 92% DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL2 DL1 DL2 Best Overall Response (%) DCR 100% -20 * • 9 cPR • 2 uPR pending confirmation -40 Best Objective Response: -60
Slide 14: Vopimetostat + daraxonrasib in MTAPdel NSCLC and PDAC: ORR 93%
Vopimetostat + daraxonrasib in MTAPdel NSCLC and PDAC: ORR 93% - 14 PRs in 15 patients 20.0 Line of therapy: N=15 2 2 2 3 3 2 4 3 3 3 3 3 1 3 2 .0 ORR 93% DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL1 DL1 DL2 Best Overall Response (%) DCR 100% -20.0 * • 12 cPR • 2 uPR pending confirmation -40.
Slide 15: Encouraging durability with vopimetostat + daraxonrasib
Encouraging durability with vopimetostat + daraxonrasib Line of Indication therapy PDAC 3 Key Metrics NSCLC 3 PDAC 3 • Two disease progressions PDAC 3 observed PDAC 2 PDAC 3 • Longest treatment ~10 months, ongoing PDAC 3 PDAC 2 ∗ • Median PFS NR (NE-NE) PDAC 2 • 90% 6-month PFS rate in PDAC 2 PDAC (
Slide 16: 72 year old woman with MTAPdel, KRAS-G12R metastatic pancreatic cancer
72 year old woman with MTAPdel, KRAS-G12R metastatic pancreatic cancer who received vopimetostat + daraxonrasib in the 3L setting Cycle 7, day 1: Baseline cPR (-52%) Response ongoing Data extract 28 May 2026. 3L, third line; cPR, confirmed partial response. 16
Slide 17: Vopimetostat + daraxonrasib was generally well tolerated
Vopimetostat + daraxonrasib was generally well tolerated Dose level 1 Dose level 1 Dose level 2 Safety Summary 200 mg vopimetostat + 200 mg vopimetostat + 250 mg vopimetostat + 100 mg daraxonrasib 100 mg daraxonrasib 100 mg daraxonrasib • No new safety signals observed PDAC, N=16 NSCLC, N=5 PDAC, N=
Slide 18: Vopimetostat + daraxonrasib has favorable RAS associated safety profile
Vopimetostat + daraxonrasib has favorable RAS associated safety profile vopimetostat 200 mg + daraxonrasib 100 mg (PDAC and lung) Pharmacokinetics and safety n=21 (TRAEs, % patients) dose level 1 Rash • Daraxonrasib AUC: 4106 hr*ng/ml (n=13, CV 40.5%) Stomatitis/Mucositis - Similar to daraxonrasib 3
Slide 19: First PRMT5 inhibitor combined with RAS inhibitors in the clinic
First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase 1 dose escalation trial Vopimetostat + zoldonrasib: • Dose escalation range: Any RAS mut vopimetostat + 200 – 250 mg vopimetostat QD + 2L+ MTAP-del/ daraxonrasib 600 – 1200 mg zoldonrasib QD RAS mut pancreatic and lung cancer vop
Slide 20: Vopimetostat + zoldonrasib was generally well tolerated
Vopimetostat + zoldonrasib was generally well tolerated Safety Summary All dose levels vopimetostat + zoldonrasib • No new safety signals observed N=34 • No discontinuations due to AEs All grades Grade 3 • One dose reduction TRAEs ≥15% • Most AEs were Grade 1 or 2 Patients with any event 28 (82) 9 (
Slide 21: Vopimetostat + zoldonrasib in MTAPdel KRAS G12D 2/3L PDAC: ORR 52%
Vopimetostat + zoldonrasib in MTAPdel KRAS G12D 2/3L PDAC: ORR 52% - 14 PRs in 27 patients 20 Line of therapy: 3 3 3 3 3 3 3 3 3 3 2 2 3 2 3 2 3 2 3 3 3 2 2 3 2 3 2 DL1 0 DL3 DL2 DL2 DL2 DL3 DL1 DL4 DL2 DL1 DL3 DL2 DL1 DL3 DL2 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL4 DL1 DL1 DL1 DL1 N=27 Best Overall Respons
Slide 22: Combined ORR 64% in 2/3L PDAC demonstrates clinical synergy
Combined ORR 64% in 2/3L PDAC demonstrates clinical synergy of vopimetostat + RAS(ON) inhibition N=39 20 PD ORR 64% 0 DCR 97% SD SD Best Overall Response (%) -20 SD SD SD SD SD SD SD SD PR PR PR PR PR PR -40 PR SD PR PR SD SD PR PR PR PR PR PR PR PR PR PR -60 PR PR Vopimetostat + zoldonrasib, PDAC -
Slide 23: Tango's strategy to develop vopimetostat + daraxonrasib in pancreatic cancer
Tango's strategy to potentially develop vopimetostat + daraxonrasib combination for patients with pancreatic cancer 1 Assess contribution of components Expansion of Primary Phase 1/2 study Readout 2 Explore accelerated 2L approval Primary 1L RCT Readout 3 1L approval Initiated dialogue with global r
Slide 24: Vopimetostat monotherapy
Vopimetostat monotherapy 24
Slide 25: Vopimetostat monotherapy phase 1/2 study
Vopimetostat monotherapy phase 1/2 study DOSE ESCALATION DOSE OPTIMIZATION Pancreatic cancer • Data confirmed monotherapy activity • Cohort fully enrolled with data update MTAP-del solid tumors Lung cancer anticipated in 2H 2026 Histology selective cancers • Encouraging data highlight franchise grow
Slide 26: Vopimetostat monotherapy 250 mg QD showed best-in-class safety potential
Vopimetostat monotherapy 250 mg QD showed best-in-class safety potential Related AEs in ≥5% pts (n=84) Key points • Median follow-up 6.1 months • 8% dose reduction • 0% discontinuation for related events* • No grade 4-5 related events Grade 1 • Low grade GI side effects Grade 2 Grade 3 Vopimetostat
Slide 27: Vopimetostat demonstrates clear monotherapy activity across histologies
Vopimetostat demonstrates clear monotherapy activity across histologies Active doses >6 mo follow-up Key points n=94 • ORR 27% in 16 different histologies • mPFS 6.4 months • DCR 78% • 37/94 patients ongoing • Median follow-up 9.4 months • Good tolerability with no discontinuations for drug related
Slide 28: Durable disease control with vopimetostat across cancer types
Durable disease control with vopimetostat across cancer types All tumor evaluable patients at active doses (n=131) Key points • Overall mPFS 6.4 months Partial response − PR pts 11.1 months Stable disease Progressive disease − SD pts 7.3 months − PD pts <2 months • Median time to response 3.5 months
Slide 29: Vopimetostat lung cancer cohort
Vopimetostat lung cancer cohort 41 lung cancer patients at active doses One or more prior therapy for advanced disease • n=41 patients • 12/41 pts more than 6 months since enrollment • Median follow-up 4.7 months Enrollment by starting dose (QD) • 200 mg n=13* • 250 mg n=26 • 300 mg n=2 Fully enroll
Slide 30: Vopimetostat 49% ORR in histology selective cohort
Vopimetostat 49% ORR in histology selective cohort Tumor evaluable pts at active doses with >6 months follow-up (n=37) Key points • ORR 49% • mPFS 9.1 months • DCR 89% • 21/37 patients ongoing • Median follow-up 9.5 months • Excludes sarcoma, pancreatic and lung cancer ● Ongoing Cholangiocarcinoma M
Slide 31: TNG456
TNG456 PRMT5 inhibition in MTAP-deleted cancers 31
Slide 32: TNG456 is a next-generation CNS-penetrant PRMT5 inhibitor
TNG456 is a next-generation CNS-penetrant PRMT5 inhibitor Preclinical brain penetrance provides potential to address high unmet need in glioblastoma • Predicted brain exposure well above efficacy threshold • In development for MTAP-del glioblastoma (7,000 patients/yr US)1 • Limited treatment options
Slide 33: TNG456 phase 1/2 clinical study in MTAP-del solid tumors
TNG456 phase 1/2 clinical study in MTAP-del solid tumors Summary • Dose escalation ongoing DOSE ESCALATION DOSE EXPANSION • TNG456 exposure in brain predicted to be in efficacious range at Glioblastoma achievable doses based on preclinical models MTAP del cancers NSCLC • Abemaciclib combination to s
Slide 34: Upcoming milestones and financial highlights
Upcoming milestones and financial highlights 34
Slide 35: Disciplined capital allocation focused on most promising opportunities
Disciplined capital allocation focused on most promising, value-creating opportunities Clear path forward Multiple inflection points anticipated by end of 2026 Rapidly advance 1L PDAC vopimetostat + Finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pa
Slide 36: Tango Therapeutics
Ai; TANGO therapeutics
Tango Therapeutics — Investor Presentation (August 2026) on 6ix